Authors
Liturri, M. G., Bergna, A., Lai, A., Della Ventura, C., Gabrieli, A., Seravalli, I., Ciofi-Baffoni, S., Lenci, E., Trabocchi, A., Rusconi, S.
Abstract
The SARS-CoV-2 main protease (3CLpro) is a key target for antiviral development. We investigated FT235, a peptidomimetic PROTAC linking a GC-376 warhead to pomalidomide for targeted degradation. FT235 bound 3CLpro, inhibiting activity (IC50 = 21.2 uM), and reducing protease levels in cells. In vitro data showed no cytotoxicity up to 100 uM and variant-dependent antiviral activity, with increased potency in the presence of a P-gp inhibitor. These results support PROTAC-based antivirals as promising therapeutic candidates.
Preprint server:
bioRxiv
The authors list and abstract were imported from bioRxiv on 04 Nov 2025.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 35
- Comments 0